{
    "nct_id": "NCT04041128",
    "official_title": "Pre-Surgical Window Pilot Investigation of the Effect of PARP Inhibition on the Cellular and Molecular Changes in Primary Ovarian and Breast Cancer",
    "inclusion_criteria": "* All patients must have cytology/ biopsy proven diagnosis of a mullerian carcinoma, high clinical index of suspicion for ovarian cancer OR triple negative, BRCA mutated breast cancer.\n* Patients may not have received prior treatment for breast or ovarian cancer.\n* All patients must be of at least 18 years of age.\n* ECOG Performance status must be 0,1 or 2.\n* Patients must not have received a prior PARP inhibitor\n* Adequate organ and marrow function as defined below:\n* absolute neutrophil count >/= 1500/mcL\n* Platelets > /= 100,000 /mcl\n* Hemoglobin >/= 8 g/dl\n* Total bilirubin </= 1.5 x the institutional ULN\n* AST, ALT </= 3 x the institutional ULN\n* Creatinine </= the institutional ULN\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n  * Has not undergone a hysterectomy or bilateral oophorectomy; or\n  * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n* Patients must be able to swallow and retain oral medications.\n* Ability to understand and the willingness to sign a written informed consent.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Chemotherapy, radiotherapy, or other cancer therapy within 4 weeks prior to starting study treatment. Subjects must have recovered from prior treatment-related to toxicities to grade 1 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management, such as hypothyroidism from prior immune checkpoint inhibitor treatment).\n* Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.\n* Brain metastases\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Lynparza or other agents used in study.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.\n* Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.",
    "miscellaneous_criteria": ""
}